Teva is betting big on its partnership with MedinCell for long-acting injectables, recently describing the firms’ proposed 505(b)(2) hybrid risperidone LAI as a “gamechanger” for patients – while, as it awaits near-term regulatory action, also being a potential fillip for Teva’s spluttering margins.
Now MedinCell has announced that the pair’s second product candidate, the proposed first subcutaneous LAI formulation of olanzapine also for...








